Regeneron Pharmaceuticals
REGN
Market cap $83.2B

756.81 USD

-25.70

3.28%

At close Nov 15, 4:00 PM EST

After hours

756.81

+0.00

0.00%

1 day

-3.28%

5 days

-8.15%

1 month

-25.55%

3 months

-35.61%

6 months

-22.63%

Year to date

-16.37%

1 year

-4.49%

5 years

119.45%

10 years

89.37%

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 14,176

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 29 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

22% more first-time investments, than exits

New positions opened: 134 | Existing positions closed: 110

17% more repeat investments, than reductions

Existing positions increased: 519 | Existing positions reduced: 442

2% more funds holding

Funds holding: 1,306 [Q2] → 1,330 (+24) [Q3]

4% less capital invested

Capital invested by funds: $100B [Q2] → $96.2B (-$3.9B) [Q3]

2.4% less ownership

Funds ownership: 87.96% [Q2] → 85.56% (-2.4%) [Q3]

18% less funds holding in top 10

Funds holding in top 10: 28 [Q2] → 23 (-5) [Q3]

22% less call options, than puts

Call options by funds: $1.41B | Put options by funds: $1.8B

See Fund Rankings

Research analyst outlook

29 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$895

18%

upside

Avg. target

$1,156

53%

upside

High target

$1,300

72%

upside

29 analyst ratings

24 positive

83%

5 neutral

17%

0 negative

0%

Wolfe Research Alexandria Hammond 0% 1-year accuracy 0 / 1 met price target	52%upside $1,150	Outperform Initiated	15 Nov 2024
Citigroup Geoff Meacham 42% 1-year accuracy 10 / 24 met price target	18%upside $895	Neutral Initiated	14 Nov 2024
Oppenheimer Hartaj Singh 43% 1-year accuracy 12 / 28 met price target	32%upside $1,000	Outperform Maintained	6 Nov 2024
Morgan Stanley Matthew Harrison 35% 1-year accuracy 6 / 17 met price target	56%upside $1,184	Overweight Maintained	1 Nov 2024
RBC Capital Brian Abrahams 31% 1-year accuracy 25 / 80 met price target	61%upside $1,215	Outperform Maintained	1 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 33 articles about REGN published over the past 30 days

CNBC Television

Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings

The Investment Committee give you their top stocks to watch for the second half.

Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

The Motley Fool

2 Top Growth Stocks to Buy on the Dip

Their recent issues are nothing to fret over for investors focused on the long game.

2 Top Growth Stocks to Buy on the Dip

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Regeneron Announces Investor Conference Presentations

3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt

When thinking about stocks with recession-resistant characteristics, a few key metrics come to mind. First are low-beta stocks.

3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt

The Motley Fool

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial Paris and Tarrytown, NY, November 6, 2024. The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age.

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

See News Rankings

Charts implemented using Lightweight Charts™